JP2020533016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533016A5 JP2020533016A5 JP2020529100A JP2020529100A JP2020533016A5 JP 2020533016 A5 JP2020533016 A5 JP 2020533016A5 JP 2020529100 A JP2020529100 A JP 2020529100A JP 2020529100 A JP2020529100 A JP 2020529100A JP 2020533016 A5 JP2020533016 A5 JP 2020533016A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antigen
- acid sequence
- seq
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 76
- 239000000427 antigen Substances 0.000 claims 65
- 102000036639 antigens Human genes 0.000 claims 65
- 108091007433 antigens Proteins 0.000 claims 65
- 229920001184 polypeptide Polymers 0.000 claims 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims 44
- 102000004196 processed proteins & peptides Human genes 0.000 claims 44
- 239000012634 fragment Substances 0.000 claims 35
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 12
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims 3
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023105890A JP7685771B2 (ja) | 2017-08-01 | 2023-06-28 | 二重特異性抗体およびその使用 |
| JP2025072790A JP2025111661A (ja) | 2017-08-01 | 2025-04-25 | 二重特異性抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539970P | 2017-08-01 | 2017-08-01 | |
| US62/539,970 | 2017-08-01 | ||
| US201862654112P | 2018-04-06 | 2018-04-06 | |
| US62/654,112 | 2018-04-06 | ||
| PCT/US2018/044778 WO2019028125A1 (en) | 2017-08-01 | 2018-08-01 | Bispecific antibodies and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023105890A Division JP7685771B2 (ja) | 2017-08-01 | 2023-06-28 | 二重特異性抗体およびその使用 |
| JP2025072790A Division JP2025111661A (ja) | 2017-08-01 | 2025-04-25 | 二重特異性抗体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533016A JP2020533016A (ja) | 2020-11-19 |
| JP2020533016A5 true JP2020533016A5 (enExample) | 2021-09-09 |
Family
ID=65233048
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529100A Pending JP2020533016A (ja) | 2017-08-01 | 2018-08-01 | 二重特異性抗体およびその使用 |
| JP2023105890A Active JP7685771B2 (ja) | 2017-08-01 | 2023-06-28 | 二重特異性抗体およびその使用 |
| JP2025072790A Pending JP2025111661A (ja) | 2017-08-01 | 2025-04-25 | 二重特異性抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023105890A Active JP7685771B2 (ja) | 2017-08-01 | 2023-06-28 | 二重特異性抗体およびその使用 |
| JP2025072790A Pending JP2025111661A (ja) | 2017-08-01 | 2025-04-25 | 二重特異性抗体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US12049517B2 (enExample) |
| EP (2) | EP3661555B1 (enExample) |
| JP (3) | JP2020533016A (enExample) |
| KR (2) | KR102794369B1 (enExample) |
| CN (3) | CN111356477B (enExample) |
| ES (1) | ES3023158T3 (enExample) |
| WO (1) | WO2019028125A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111356477B (zh) * | 2017-08-01 | 2024-08-30 | Ab工作室有限公司 | 双特异性抗体及其用途 |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| WO2020177717A1 (zh) * | 2019-03-04 | 2020-09-10 | 上海一宸医药科技有限公司 | 新型双特异性结合分子及其药物偶联物 |
| WO2020198683A1 (en) * | 2019-03-28 | 2020-10-01 | Ab Studio Inc. | Heteromultimeric proteins and methods of use thereof |
| PE20230160A1 (es) * | 2019-12-17 | 2023-02-01 | Pfizer | Anticuerpos especificos para cd47, pd-l1 y sus usos |
| CN112062855B (zh) * | 2020-08-26 | 2024-08-30 | 北京天诺健成医药科技有限公司 | 一种含有衔接器的药物治疗剂的开发和应用 |
| WO2022100694A1 (zh) * | 2020-11-12 | 2022-05-19 | 迈威(上海)生物科技股份有限公司 | 抗体及其制备方法 |
| CN112430271B (zh) * | 2020-11-13 | 2021-09-03 | 武汉滨会生物科技股份有限公司 | 一种双特异性单链抗体及应用 |
| CN118369340A (zh) * | 2021-11-25 | 2024-07-19 | 盛禾(中国)生物制药有限公司 | 一种双特异性抗原结合蛋白 |
| CN116143948A (zh) * | 2023-02-14 | 2023-05-23 | 中国药科大学 | 一种以Jurkat为平台的靶向CD24和PD-L1双特异性嵌合抗原受体CAR及其应用 |
| WO2024255756A1 (zh) * | 2023-06-13 | 2024-12-19 | 南京维立志博生物科技股份有限公司 | 基于共同轻链产生双特异性抗体的方法 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| EP1645635A3 (en) | 1989-08-18 | 2010-07-07 | Oxford Biomedica (UK) Limited | Replication defective recombinant retroviruses expressing a palliative |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CN100522999C (zh) * | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
| JP2005538738A (ja) * | 2002-09-16 | 2005-12-22 | エリューシス セラピューティクス，インコーポレーテッド | 抗原結合性抗体フラグメントに架橋された抗ｃｒ１抗体を含む二重特異性分子 |
| WO2004065611A1 (ja) * | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体の軽鎖スクリーニング方法 |
| CA2522586C (en) | 2003-05-31 | 2017-02-21 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| EP1876236B9 (en) * | 2005-04-08 | 2015-02-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| US8394926B2 (en) | 2005-12-21 | 2013-03-12 | Micromet Ag | Pharmaceutical compositions with resistance to soluble CEA |
| EP2009101B1 (en) * | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| EP2037961B1 (en) * | 2006-06-14 | 2015-11-11 | MacroGenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| MX368932B (es) * | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| EP2785375B1 (en) * | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| PL2794905T3 (pl) | 2011-12-20 | 2020-11-02 | Medimmune, Llc | Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych |
| ES2812849T3 (es) | 2012-02-24 | 2021-03-18 | Abbvie Stemcentrx Llc | Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| AU2013259276B2 (en) * | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| CA2878843A1 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Bispecific asymmetric heterodimers comprising anti-cd3 constructs |
| AU2013302696B9 (en) * | 2012-08-14 | 2018-08-09 | Ibc Pharmaceuticals, Inc. | T-cell redirecting bispecific antibodies for treatment of disease |
| UA128182C2 (uk) | 2012-11-13 | 2024-05-01 | Біонтех Аґ | Агенти для лікування експресуючих клаудин ракових захворювань |
| EP4324480A3 (en) | 2013-05-20 | 2024-05-08 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| MX2016000272A (es) * | 2013-07-12 | 2016-08-03 | Zymeworks Inc | Construcciones de unión a los antígenos cd19 y cd3 biespecificos. |
| RU2016115866A (ru) * | 2013-10-11 | 2017-11-16 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи |
| JP6510532B2 (ja) | 2013-12-20 | 2019-05-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性ｈｅｒ２抗体及び使用方法 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| CA2938933A1 (en) * | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| EA201790871A1 (ru) | 2014-11-11 | 2017-11-30 | Амуникс Оперэйтинг Инк. | Нацеленные конъюгатные композиции xten и способы их получения |
| CN116333153A (zh) | 2014-11-26 | 2023-06-27 | 森科股份有限公司 | 结合cd3和肿瘤抗原的异二聚体抗体 |
| CN110658340B (zh) * | 2015-01-08 | 2023-10-31 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
| CN114478792A (zh) * | 2015-01-08 | 2022-05-13 | 根马布股份公司 | 针对cd3和cd20的双特异性抗体 |
| EP3242889A4 (en) * | 2015-01-09 | 2018-09-26 | Immunomedics, Inc. | Tumor therapy by bispecific antibody pretargeting |
| US10464999B2 (en) * | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3345928B1 (en) * | 2015-07-10 | 2020-06-24 | Merus N.V. | Human cd3 binding antibody |
| US11034765B2 (en) | 2015-10-02 | 2021-06-15 | Symphogen A/S | Anti-PD-1 antibodies and compositions |
| KR20180085800A (ko) * | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| WO2017106462A1 (en) * | 2015-12-18 | 2017-06-22 | Biogen Ma Inc. | Bispecific antibody platform |
| CN111356477B (zh) * | 2017-08-01 | 2024-08-30 | Ab工作室有限公司 | 双特异性抗体及其用途 |
-
2018
- 2018-08-01 CN CN201880062833.7A patent/CN111356477B/zh active Active
- 2018-08-01 ES ES18840836T patent/ES3023158T3/es active Active
- 2018-08-01 WO PCT/US2018/044778 patent/WO2019028125A1/en not_active Ceased
- 2018-08-01 EP EP18840836.3A patent/EP3661555B1/en active Active
- 2018-08-01 CN CN202111079150.2A patent/CN113896797B/zh active Active
- 2018-08-01 CN CN202411097878.1A patent/CN119019564A/zh active Pending
- 2018-08-01 US US16/635,878 patent/US12049517B2/en active Active
- 2018-08-01 EP EP22160823.5A patent/EP4088783A1/en active Pending
- 2018-08-01 KR KR1020207006195A patent/KR102794369B1/ko active Active
- 2018-08-01 KR KR1020257011307A patent/KR20250052490A/ko active Pending
- 2018-08-01 JP JP2020529100A patent/JP2020533016A/ja active Pending
-
2021
- 2021-08-10 US US17/398,853 patent/US11440972B2/en active Active
- 2021-08-10 US US17/398,807 patent/US11566083B2/en active Active
-
2023
- 2023-06-28 JP JP2023105890A patent/JP7685771B2/ja active Active
-
2024
- 2024-06-14 US US18/743,295 patent/US20240336702A1/en active Pending
-
2025
- 2025-04-25 JP JP2025072790A patent/JP2025111661A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533016A5 (enExample) | ||
| JP2019527553A5 (enExample) | ||
| JP2025160458A5 (enExample) | ||
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| JP2019532619A5 (enExample) | ||
| JP2020536504A5 (enExample) | ||
| JP2018516853A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| JP2018523493A5 (enExample) | ||
| CA2583910A1 (en) | Angiopoietin-2 specific binding agents | |
| WO2012163520A4 (en) | Dual targeting | |
| JP2013506428A5 (enExample) | ||
| JP2017504578A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP2020534830A5 (enExample) | ||
| CA3093008C (en) | Monoclonal antibodies that bind to the embryonic stage-specific antigen 4 and their uses | |
| JP2018505681A5 (enExample) | ||
| RU2018102803A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2018525320A5 (enExample) | ||
| IL280487B2 (en) | Anti-mica/b antibodies that block mica/b shedding and methods of use | |
| JP2017524362A5 (enExample) | ||
| CN115461373A (zh) | 密蛋白18.2的抗体及其用途 | |
| MY206255A (en) | Humanized anti-vegf monoclonal antibody | |
| JPWO2021104371A5 (enExample) | ||
| JP2020518243A5 (enExample) |